Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 50% Improvement Relative Risk ICU admission 50% Hospitalization time 9% Sub-intensive hospitaliza.. 39% NIV time 58% High flow oxygen time 8% Sleep time 18% Delirium 33% c19early.org/j Bologna et al. Melatonin for COVID-19 LATE TREATMENT Is late treatment with melatonin beneficial for COVID-19? Retrospective 80 patients in Italy Lower need for oxygen therapy with melatonin (p<0.000001) Bologna et al., J. Clinical Medicine, doi:10.3390/jcm10245857 Favors melatonin Favors control
Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study
Bologna et al., Journal of Clinical Medicine, doi:10.3390/jcm10245857
Bologna et al., Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for.., Journal of Clinical Medicine, doi:10.3390/jcm10245857
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 40 hospitalized patients in Italy treated with melatonin and 40 control patients, showing improved sleep, reduced delirium, shorter hospitalization and oxygen times, and reduced ICU admission and mortality (not statistically significant).
risk of death, 50.0% lower, RR 0.50, p = 0.48, treatment 3 of 40 (7.5%), control 6 of 40 (15.0%), NNT 13.
risk of ICU admission, 50.0% lower, RR 0.50, p = 0.48, treatment 3 of 40 (7.5%), control 6 of 40 (15.0%), NNT 13.
hospitalization time, 8.7% lower, relative time 0.91, p = 0.05, treatment mean 31.3 (±6.8) n=40, control mean 34.3 (±6.9) n=40.
relative sub-intensive hospitalization time, 38.8% better, relative time 0.61, p < 0.001, treatment mean 12.3 (±3.0) n=40, control mean 20.1 (±6.1) n=40.
relative NIV time, 58.4% better, relative time 0.42, p < 0.001, treatment mean 5.2 (±3.0) n=40, control mean 12.5 (±4.2) n=40.
relative high flow oxygen time, 7.8% better, relative time 0.92, p = 0.35, treatment mean 7.1 (±2.5) n=40, control mean 7.7 (±3.2) n=40.
relative sleep time, 18.2% better, RR 0.82, p < 0.001, treatment mean 5.5 (±0.8) n=40, control mean 4.5 (±1.2) n=40.
delirium, 33.3% lower, RR 0.67, p < 0.001, treatment mean 2.2 (±1.1) n=40, control mean 3.3 (±1.3) n=40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bologna et al., 14 Dec 2021, retrospective, Italy, peer-reviewed, 3 authors.
Contact: carolina.bologna@libero.it.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Abstract: Journal of Clinical Medicine Article Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study Carolina Bologna * , Pasquale Madonna and Eduardo Pone UO Pneumologia Subintensiva COVID Ospedale del Mare ASL Na1, 80147 Naples, Italy; linomadonna@libero.it (P.M.); eddi22@alice.it (E.P.) * Correspondence: carolina.bologna@libero.it; Tel.: +39-34-7300-2271   Citation: Bologna, C.; Madonna, P.; Pone, E. Efficacy of Prolonged-Release Abstract: Background: we have observed the effect of insomnia treatment in clinical and prognostic differences of patients admitted for COVID-19 pneumonia in respiratory sub-intensive units that were administered a prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a group of patients out of therapy. Materials and Methods: We evaluated 40 patients on prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a control group of 40 patients out of therapy. Results: patients in the PRM 2 mg group had a shorter duration of therapy with non-invasive ventilation (5.2 ± 3.0 vs. 12.5 ± 4.2; p < 0.001), with a shorter stay in sub-intensive care (12.3 ± 3.2 vs. 20.1 ± 6.1; p < 0.001), and, therefore, a shorter overall duration of hospitalization (31.3 ± 6.8 vs. 34.3 ± 6.9 p = 0.03). In addition, a lower incidence of delirium was found (2.2 ± 1.1 vs. 3.3 ± 1.3; p < 0.001). Conclusions: A significant increase in sleep hours and a reduction in delirium episodes occurs in hospitalized insomniac patients treated with PRM 2 mg, compared to untreated patients. Based on these preliminary results, we can assume that there are benefits of prolonged-release melatonin 2 mg in COVID-19 therapy. Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients Keywords: COVID; SARS-CoV; prolonged-release melatonin 2 mg; delirium; insomnia for COVID-19: A Retrospective Observational Study. J. Clin. Med. 2021, 10, 5857. https://doi.org/ 10.3390/jcm10245857 Academic Editor: Pierpaolo Di Micco Received: 8 November 2021 Accepted: 10 December 2021 Published: 14 December 2021 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit